HK1220187A1 - 抗焦慮化合物的晶型 - Google Patents

抗焦慮化合物的晶型

Info

Publication number
HK1220187A1
HK1220187A1 HK16108206.5A HK16108206A HK1220187A1 HK 1220187 A1 HK1220187 A1 HK 1220187A1 HK 16108206 A HK16108206 A HK 16108206A HK 1220187 A1 HK1220187 A1 HK 1220187A1
Authority
HK
Hong Kong
Prior art keywords
crystalline form
anxiolytic compound
anxiolytic
compound
crystalline
Prior art date
Application number
HK16108206.5A
Other languages
English (en)
Inventor
Bernard Luke Flynn
Dharam Paul
Andrew John Harvey
Original Assignee
Bionomics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionomics Ltd filed Critical Bionomics Ltd
Publication of HK1220187A1 publication Critical patent/HK1220187A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK16108206.5A 2013-03-15 2016-07-13 抗焦慮化合物的晶型 HK1220187A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361787436P 2013-03-15 2013-03-15
AU2013204159A AU2013204159B2 (en) 2013-03-15 2013-04-12 A Crystalline Form of an Anxiolytic Compound
PCT/AU2013/000497 WO2014138772A1 (en) 2013-03-15 2013-05-14 A crystalline form of an anxiolytic compound

Publications (1)

Publication Number Publication Date
HK1220187A1 true HK1220187A1 (zh) 2017-04-28

Family

ID=51628585

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16108206.5A HK1220187A1 (zh) 2013-03-15 2016-07-13 抗焦慮化合物的晶型

Country Status (10)

Country Link
US (2) US9758516B2 (zh)
EP (1) EP2970290B1 (zh)
JP (2) JP2016510767A (zh)
CN (2) CN105377850A (zh)
AU (2) AU2013204159B2 (zh)
CA (1) CA2905573C (zh)
HK (1) HK1220187A1 (zh)
MX (1) MX369451B (zh)
NZ (1) NZ712341A (zh)
WO (1) WO2014138772A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9745296B2 (en) * 2013-03-15 2017-08-29 Bionomics Limited Salts, co-crystals, and polymorphs of an anxiolytic compound
WO2018102885A1 (en) * 2016-12-09 2018-06-14 Bionomics Limited Modulators of nicotinic acetylcholine receptors and uses thereof
WO2019109150A1 (en) * 2017-12-07 2019-06-13 Bionomics Limited Methods of treating agitation
MX2022003347A (es) * 2019-09-23 2022-04-11 Bionomics Ltd Formulaciones terapeuticas y usos de las mismas.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2058061T3 (es) * 1985-10-25 1994-11-01 Beecham Group Plc Derivado de piperidina, su preparacion y su uso como medicamento.
CA2563793A1 (en) * 2004-05-07 2005-11-24 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
JP5373613B2 (ja) * 2006-10-16 2013-12-18 バイオノミクス リミテッド 新規な抗不安薬化合物
WO2012116410A1 (en) * 2011-03-02 2012-09-07 Bionomics Limited Methods of treating a disease or condition of the central nervous system
US9133188B2 (en) * 2011-05-12 2015-09-15 Bionomics Limited Methods for preparing naphthyridines

Also Published As

Publication number Publication date
EP2970290B1 (en) 2020-07-22
AU2013204159B2 (en) 2015-05-07
AU2013382559A1 (en) 2015-09-24
NZ712341A (en) 2019-07-26
US9758516B2 (en) 2017-09-12
MX2015013048A (es) 2016-09-07
CN105377850A (zh) 2016-03-02
EP2970290A1 (en) 2016-01-20
CA2905573A1 (en) 2014-09-18
JP2018109011A (ja) 2018-07-12
AU2013204159A1 (en) 2014-10-02
US20170305905A1 (en) 2017-10-26
JP2016510767A (ja) 2016-04-11
MX369451B (es) 2019-11-08
CA2905573C (en) 2021-03-02
EP2970290A4 (en) 2016-08-31
CN107814799A (zh) 2018-03-20
US20160039810A1 (en) 2016-02-11
WO2014138772A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
IL249518A0 (en) A compound that inhibits trk
GB201311891D0 (en) Novel compound
HK1222393A1 (zh) 新的喹啉取代的化合物
SI3008039T1 (sl) Kristalinična oblika MDM2 inhibitorja
EP2982666A4 (en) HETEROCYCLIC COMPOUND
GB201302368D0 (en) Compound
EP3018126A4 (en) HETEROCYCLIC COMPOUND
HK1219100A1 (zh) 吡啶基吡唑並喹啉化合物
EP2980089A4 (en) HETEROCYCLIC CONNECTION
HRP20190133T1 (hr) Heterociklički spoj
EP2982670A4 (en) HETEROCYCLIC COMPOUND
HK1220187A1 (zh) 抗焦慮化合物的晶型
EP2947066A4 (en) PHENOXYALKYLAMINVERBINDUNG
HK1220458A1 (zh) 化合物之多晶型物及鹽
GB201307331D0 (en) Compound
IL245386A0 (en) A crystalline beta-lactamase inhibitor
EP2970188A4 (en) NOVEL CRYSTALLINE FORMS
GB201300903D0 (en) Crystalline Form
SG11201507988PA (en) Method of manufacturing acetylene compound
GB201322438D0 (en) Compound
GB201315772D0 (en) Compound
GB201305634D0 (en) Compound
GB201304250D0 (en) Compound
GB201301585D0 (en) Compound